Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not mainly eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011. It is grouped under the following drug class(es): DPP-4 inhibitors and Hypoglycemics. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Linagliptina, Tradjenta and Trajenta. Its PubChem CID is 10096344.
Linagliptin
| CAS No | 668270-12-0 |
|---|---|
| Molecular Formula | C25H28N8O2 |
| Molecular Weight | 472.50 g/mol |
| Synonyms | 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not mainly eliminated by the renal system, and obeys concentration dependant protein binding.
The listed CAS number is 668270-12-0.
The listed molecular formula is C25H28N8O2.
The listed molecular weight is 472.50 g/mol.
8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione.
The source lists Linagliptina, Tradjenta and Trajenta.